Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus URESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus URESE.
ETHACRYNATE SODIUM vs URESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Urease inhibitor; reduces bacterial conversion of urea to ammonia, lowering urine pH and ammonia concentration.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
Oral: 20 mg once daily. May increase to 40 mg once daily if needed after 4 weeks. Maximum: 40 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
4-6 hours; prolonged in renal impairment (up to 12-15 hours in anuria).
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Loop Diuretic
Loop Diuretic